##1. Limitations of GWAS: Tracing the True Causal Variants Obscured by Linkage Disequilibrium (LD) Genome-wide association studies (GWAS) have identified tens of thousands of genetic loci associated with disease, yet pinpointing the true causal variant that drives disease has remained challenging. Because genes are often located in close proximity and inherited as linked blocks—a phenomenon known as linkage disequilibrium (LD)—distinguishing the single variant that exerts a biological effect from the many statistically significant variants has been a major barrier in genomic medicine.

##2. Bayesian Fine-Mapping: Precise Integration of Statistics and Functional Annotation To address the LD challenge, the research team applied a genome-wide Bayesian fine‑mapping approach. This method goes beyond simple statistical metrics by integrating functional annotation data that indicate whether a variant resides in a protein‑altering region or a regulatory element influencing gene expression. By computing the posterior probability that each variant is causal and dramatically narrowing the credible set of variants with high probability, the approach captured hundreds of novel causal variants at high resolution that were previously hidden within association signals.

##3. From Variants to Therapeutic Targets: Reconstructing Biological Pathways The causal variants identified through fine‑mapping defined key genes and the biological pathways they participate in, reshaping our understanding of disease mechanisms. Notably, a substantial proportion of the newly discovered causal variants map directly to genes that are already targets of approved drugs or compounds in development. This provides a concrete genetic roadmap that can dramatically accelerate the drug‑target validation stage, linking genetic discoveries to therapeutic development.

##4. Why it Matters: An Engine Converting Genomic Big Data into Actionable Prescriptions The significance of this work lies in elevating genomic findings from mere statistical associations to biological causality. Knowing the true causal variant enables prediction of an individual’s genetic risk at the level of molecular mechanisms rather than as a simple score. Consequently, fine‑mapping uncovers the therapeutic switches hidden within genomic big data, positioning genomic medicine to move beyond theoretical analysis and deliver personalized prevention and treatment solutions at the point of care. This represents a pivotal technological driver for translating genomic insights into actionable clinical practice.